Quest Diagnostics Incorporated (DGX)

Market Cap	18.01B
Revenue (ttm)	9.54B
Net Income (ttm)	838.00M
Shares Out	111.62M
EPS (ttm)	7.44
PE Ratio	21.69
Forward PE	17.06
Dividend	$3.00 (1.86%)
Ex-Dividend Date	Oct 4, 2024

Volume	763,760
Open	161.38
Previous Close	161.16
Day's Range	160.05 - 162.02
52-Week Range	123.04 - 162.88
Beta	0.89
Analysts	Buy
Price Target	163.38 (+1.28%)
Earnings Date	Oct 22, 2024

About DGX

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, govern...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Dec 17, 1996
• Employees: 48,000
• Stock Exchange: NYSE
• Ticker Symbol: DGX
• Website: https://www.questdiagnostics.com

Financial Performance

In 2023, Quest Diagnostics's revenue was $9.25 billion, a decrease of -6.38% compared to the previous year's $9.88 billion. Earnings were $850.00 million, a decrease of -9.77%.

Analyst Forecast

According to 13 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is $163.38, which is an increase of 1.28% from the latest price.

Price Target

$163.38

(1.28% upside)

Analyst Consensus: Buy